semaglutide heart racing FDA Clears For Cardiac Risk Reduction in Diabetic Patients Semaglutide Shows Secondary Cardiovascular Prevention

Tirzepatide, a dual GLP-1 / glucose-dependent insulinotropic polypeptide (GIP) agonist, was superior to semaglutide in reducing HbA 1c and body weight in the SURPASS-2 trial, a phase 3, randomised, open-label trial comparing the efficacy and safety of tirzepatide vs semaglutide once weekly as add-on therapy to metformin in individuals with type 2 diabetes [10]

Gut dysbiosis and increased intestinal permeability (leaky gut) are now considered major contributors to chronic metabolic inflammation

Cerebrovascular pathology, including atherosclerosis and microangiopathy, evolves insidiously over several decades [22]

PlexusDx recommends optimizing tirzepatide monotherapy first